GlassScriptPhysician profile
Ryan Hankins
NPI 1164712469
$28,507.90
in general payments reported to CMS, 2019-2025
28 companies · $6,280 in 2025
The $6,280 reported for 2025 was more than what 92% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,145 · 2020: $930 · 2021: $508 · 2022: $2,084 · 2023: $6,837 · 2024: $11K · 2025: $6,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,905 · Travel and Lodging: $3,022 · Food and Beverage: $2,363 · Education: $1.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,550.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,905.00 |
| Travel and Lodging | $3,022.07 |
| Food and Beverage | $2,362.76 |
| Education | $1.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $23,360.72 | 2019-2025 | Spaceoar System, Spaceoar Vue System - 10ml, Ams 700 |
| Angiodynamics, INC. | $1,799.26 | 2025 | Nanoknife |
| Neotract INC. | $736.93 | 2019-2020 | |
| Urogen Pharma, INC. | $297.84 | 2020-2025 | |
| Procept Biorobotics Corporation | $274.07 | 2019-2025 | Aquabeam System |
| Abbott Laboratories | $255.10 | 2019-2020 | |
| Integra Lifesciences Corporation | $243.54 | 2020 | |
| Corcept Therapeutics | $209.16 | 2022-2024 | Korlym |
| Antares Pharma, INC. | $206.01 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $190.77 | 2023-2025 | Gemtesa |
| Endo Pharmaceuticals INC. | $161.95 | 2019-2024 | Xiaflex |
| Baxter Healthcare | $121.95 | 2019 | |
| Progenics Pharmaceuticals, INC. | $96.03 | 2022 | |
| Tolmar, INC. | $91.66 | 2025 | Jatenzo, Eligard |
| Urovant Sciences INC | $83.31 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $62.32 | 2024-2025 | |
| C. R. Bard, INC. & Subsidiaries | $46.87 | 2023 | Bard Urinary Drainage Bag |
| Laborie Medical Technologies Corp. | $44.94 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Astellas Pharma US INC | $41.17 | 2019 | |
| Axonics, INC. | $35.00 | 2022 | |
| Intuitive Surgical, INC. | $28.00 | 2019 | |
| Janssen Biotech, INC. | $25.50 | 2025 | Erleada |
| Endo USA, INC. | $23.04 | 2025 | Xiaflex |
| Accord Healthcare, INC. | $20.77 | 2022 | |
| Calyxo, INC. | $18.95 | 2025 | Cvac Aspiration System |
| Valencia Technologies Corporation | $17.20 | 2025 | Ecoin Device Kit |
| Myriad Genetic Laboratories, INC. | $14.74 | 2025 | Prolaris |
| Travere Therapeutics, INC. | $1.10 | 2023 | Thiola |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Hankins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.